Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative vs Postoperative CapeOX for Colon Cancer
NCT03125980Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- May 2017
- Primary completion
- May 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in colon cancer (2 arms), sponsored by Fudan University. Primary endpoint: 3-year disease free survival. Started May 2017; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03125980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125980.